Pourquoi le BPC-157 n'est-il pas approuvé par la FDA? La réponse des brevets

The most common explanation you will read is that peptides like BPC-157 “can’t be patented”, so nobody funds the trials. That is close to the truth but wrong in an important way — and the accurate version is more interesting, because it also explains why the pharmaceutical industry poured billions into a different group of peptides at exactly the same time it ignored this one.

The claim, stated precisely

It is not true that these compounds cannot be patented. BPC-157 has been the subject of patent filings since the 1990s, and more have been filed recently covering formulations and combination uses.

What is true is narrower and matters more: you generally cannot obtain a composition-of-matter patent on a naturally occurring peptide sequence. That is the specific kind of patent the pharmaceutical business is built on, and without it the economics of drug development collapse.

Why composition-of-matter is the patent that counts

A composition-of-matter patent covers the molecule itself. Whoever holds it controls that substance for any use, by anyone, for the life of the patent. It is the strongest protection in pharmaceuticals and it is what justifies spending hundreds of millions on clinical trials — because at the end you own the thing you proved works.

The alternatives are much weaker:

• Method-of-use patents cover using a known compound for a particular purpose. A competitor can market the same molecule for a different indication.
• Formulation and salt patents cover a specific preparation. A competitor can formulate it differently.
• Combination patents cover the compound alongside something else. A competitor can sell it alone.

All of these can be designed around. A composition-of-matter patent cannot.

Two reasons a natural sequence fails

It is a product of nature

Patent law in the United States and elsewhere excludes naturally occurring substances from patent eligibility on the principle that they are discovered rather than invented — a doctrine the Supreme Court reinforced in the Myriad gene-patenting decision. Where a claimed peptide’s amino acid sequence is identical to a sequence found in nature, isolating or synthesising it does not make it patentable subject matter.

BPC-157 illustrates the point. It is a fifteen amino acid fragment of a protein found in human gastric juice. Producing it synthetically does not change what it is.

It is no longer novel

The second barrier is simpler and applies even where the first does not. A patent requires novelty, and once a sequence has been published in the scientific literature it is prior art — against the whole world, including the researchers who published it. Many of the compounds in this category were characterised in academic papers decades ago, which put their sequences permanently into the public domain.

Publishing your discovery is how science works. It is also how you lose the ability to patent it.

The counter-example that proves it

Here is why the “peptides can’t be patented” version falls apart: some of the most valuable pharmaceutical products in the world right now are peptides.

Semaglutide and tirzepatide are peptides. They are protected by dense patent portfolios and they generate enormous revenue. So peptides are clearly patentable — which invites the obvious question of what makes them different.

The answer is that they are heavily modified, and the modifications are the invention. Semaglutide is not natural GLP-1. Its sequence carries a substitution at position 8 that resists the enzyme which would otherwise degrade it within minutes, another substitution at position 34, and a C18 fatty diacid chain attached through a spacer that makes it bind to albumin and extends its half-life to about a week. Tirzepatide is similarly lipidated and engineered to act at two receptors at once.

Every one of those changes is a deliberate design decision producing a molecule that does not exist in nature. That is an invention, it is patentable, and it is what justified the trials.

What this actually explains

So the picture is not that industry ignores peptides. It is that industry pursues peptides it can own and has no mechanism for funding trials on peptides it cannot.

The numbers are unforgiving. Taking a compound through the full clinical programme required for approval runs into the hundreds of millions of dollars over a decade or more, with most candidates failing somewhere along the way. That expenditure only makes sense if success yields a period of exclusivity to recover it. For a molecule anyone can synthesise and sell the moment it is approved, there is no commercial case — and nobody else is positioned to fund a programme at that scale.

The result is a category of compounds with genuinely interesting preclinical literature and no route to the evidence that would settle anything.

The part that gets misused

This explanation is frequently deployed to imply something it does not support: that these compounds are proven and merely suppressed.

They are not. The absence of trials means the evidence genuinely does not exist. An unpatentable compound is not a compound that was tested and buried — it is simply one the approval pipeline passed over. The honest reading of the patent argument is that the human question remains open for economic reasons, not scientific ones.

That is a considerably less satisfying story than a conspiracy, and it is the accurate one. It is also why the BPC-157 literature is almost entirely animal work, and why no regulator has assessed the compound for safety or efficacy in people.

What it means when buying

Practically, the takeaway is about vendor claims rather than chemistry. A compound with no approved indication anywhere has no established efficacy to sell, which means any vendor stating outcomes is making them up. The patent argument explains why the evidence is thin. It does not fill the gap.

Frequently asked questions

Why is BPC-157 not FDA approved?

Because the large trials approval requires have never been funded. No company has funded them, largely because a naturally occurring peptide sequence cannot receive the composition-of-matter patent that would let a sponsor recover the cost of a trial programme.

Can peptides be patented at all?

Yes — modified peptides are patented extensively. Semaglutide and tirzepatide are both peptides protected by substantial patent portfolios. What generally cannot be patented is a peptide whose sequence occurs in nature, or one whose sequence was published long enough ago to count as prior art.

Does BPC-157 have any patents?

Yes, several — covering salts, formulations and combination uses, with filings dating back to the 1990s. None of them amount to composition-of-matter control over the sequence itself, which is the protection that would justify funding a clinical programme.

Why did pharmaceutical companies develop semaglutide but not BPC-157?

Because semaglutide is a heavily engineered molecule — substitutions plus a fatty acid chain that extends its half-life to roughly a week — and those modifications are patentable inventions. BPC-157 is a fragment of a naturally occurring protein, so there is nothing comparable to own.

Does the lack of a patent mean a compound was suppressed?

No, and this is the most common misreading. It means the trials were never run — an economic outcome, not a scientific verdict. That is different from evidence existing and being hidden.